CCT8

Summary

CCT8 (chaperonin containing TCP1 subunit 8, HGNC:1623) is a protein-coding gene on chromosome 21q21.3, encoding T-complex protein 1 subunit theta (P50990). Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of actin, tubulin and other proteins upon ATP hydrolysis. It is a common-essential gene (DepMap: required in 98.9% of cancer cell lines).

This gene encodes the theta subunit of the CCT chaperonin, which is abundant in the eukaryotic cytosol and may be involved in the transport and assembly of newly synthesized proteins. Alternative splicing results in multiple transcript variants of this gene. A pseudogene related to this gene is located on chromosome 1.

Source: NCBI Gene 10694 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 3
• Clinical variants (ClinVar): 93 total
• GTEx eGene: eQTL in 49 tissues, sQTL in 27 (q < 0.05)
• Cancer dependency (DepMap): dependent in 98.9% of screened cell lines (common-essential)
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.29 (highly constrained)
• MANE Select transcript: NM_006585
• Interaction hub: 3,396 STRING partners (top 2% of genes corpus-wide)
• Notable: 93 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1623
Approved symbol	CCT8
Name	chaperonin containing TCP1 subunit 8
Location	21q21.3
Locus type	gene with protein product
Status	Approved
Aliases	Cctq, PRED71
Ensembl gene	ENSG00000156261
Ensembl biotype	protein_coding
OMIM	617786
Entrez	10694

Gene structure

Transcript identifiers

Ensembl transcripts: 38 — 19 protein_coding, 12 nonsense_mediated_decay, 4 protein_coding_CDS_not_defined, 3 retained_intron

MANE Select: ENST00000286788

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 5, TSL 3: 2, TSL 5: 2

ENST00000286788, ENST00000431234, ENST00000432178, ENST00000470450, ENST00000475205, ENST00000480359, ENST00000481059, ENST00000484403, ENST00000494296, ENST00000496121, ENST00000540844, ENST00000626972, ENST00000852626, ENST00000852627, ENST00000852628, ENST00000852629, ENST00000852630, ENST00000936253, ENST00000936254, ENST00000936255, ENST00000936256, ENST00000936257, ENST00000960004, ENST00000960005, ENST00000960006, ENST00001002166, ENST00001034075, ENST00001034079, ENST00001034081, ENST00001034082, ENST00001034083, ENST00001085360, ENST00001085361, ENST00001085364, ENST00001085369, ENST00001085370, ENST00001103464, ENST00001131824

RefSeq mRNA: 4 — MANE Select: NM_006585 NM_001282907, NM_001282908, NM_001282909, NM_006585

CCDS: CCDS33528, CCDS68181

Canonical transcript exons

ENST00000286788 — 15 exons

Exon	Start	End
ENSE00001504993	29073531	29073648
ENSE00003525940	29060541	29060660
ENSE00003573058	29056326	29056552
ENSE00003598993	29069423	29069502
ENSE00003644939	29070247	29070337
ENSE00004283619	29067556	29067705
ENSE00004283620	29064968	29065105
ENSE00004283621	29066891	29067071
ENSE00004283622	29063352	29063530
ENSE00004283623	29062128	29062243
ENSE00004283624	29066716	29066777
ENSE00004283625	29061253	29061417
ENSE00004283626	29062490	29062556
ENSE00004283627	29061496	29061567
ENSE00004283628	29062328	29062415

Expression profiles

Bgee: expression breadth ubiquitous, 302 present calls, max score 99.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 144.5411 / max 2820.5614, expressed in 1826 samples.

Highest expression (Bgee): oocyte, secondary oocyte, primordial germ cell in gonad, cortical plate, epithelium of nasopharynx.

Genetic regulation across tissues (GTEx eQTL / sQTL)

CCT8 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 49 tissues and its splicing (sQTL) in 27 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 76 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Adipose Subcutaneous	eqtl	2.0e-104	+0.68	21:29073627:G:A
Nerve Tibial	eqtl	2.2e-87	+0.55	21:29073627:G:A
Cells EBV-transformed lymphocytes	eqtl	1.3e-86	+0.98	21:29073627:G:A
Skin Sun Exposed Lower leg	eqtl	1.6e-85	+0.50	21:29073627:G:A
Cells Cultured fibroblasts	eqtl	4.7e-82	+0.36	21:29073627:G:A
Skin Not Sun Exposed Suprapubic	eqtl	1.1e-61	+0.52	21:29073627:G:A
Breast Mammary Tissue	eqtl	2.2e-60	+0.56	21:29073627:G:A
Esophagus Mucosa	eqtl	3.6e-60	+0.32	21:29073627:G:A
Thyroid	eqtl	5.7e-58	+0.48	21:29073627:G:A
Adipose Visceral Omentum	eqtl	1.1e-52	+0.46	21:29073627:G:A
Colon Transverse	eqtl	4.3e-52	+0.47	21:29073627:G:A
Whole Blood	eqtl	2.3e-50	+0.42	21:29073627:G:A
Pancreas	eqtl	3.9e-48	+0.53	21:29073627:G:A
Stomach	eqtl	4.2e-37	+0.44	21:29073627:G:A
Spleen	eqtl	2.8e-36	+0.53	21:29073627:G:A
Lung	eqtl	3.8e-34	+0.37	21:29073627:G:A
Ovary	eqtl	1.8e-31	+1.01	21:29073627:G:A
Colon Sigmoid	eqtl	2.1e-30	+0.42	21:29073627:G:A
Artery Tibial	eqtl	1.6e-29	+0.44	21:29073627:G:A
Adipose Subcutaneous	sqtl	2.9e-26	-0.91	21:29060236:G:A

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
190069	143.9133	1826
190067	0.6278	301

Top tissues by expression

showing 100 of 303 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	99.44	gold quality
secondary oocyte	CL:0000655	99.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	99.34	gold quality
cortical plate	UBERON:0005343	99.33	gold quality
epithelium of nasopharynx	UBERON:0001951	99.31	gold quality
nasopharynx	UBERON:0001728	99.30	gold quality
embryo	UBERON:0000922	99.16	gold quality
ganglionic eminence	UBERON:0004023	99.13	gold quality
endothelial cell	CL:0000115	99.12	gold quality
germinal epithelium of ovary	UBERON:0001304	98.98	gold quality
adrenal tissue	UBERON:0018303	98.92	gold quality
choroid plexus epithelium	UBERON:0003911	98.89	gold quality
ventricular zone	UBERON:0003053	98.87	gold quality
cartilage tissue	UBERON:0002418	98.86	gold quality
islet of Langerhans	UBERON:0000006	98.74	gold quality
parietal pleura	UBERON:0002400	98.55	gold quality
right adrenal gland	UBERON:0001233	98.53	gold quality
pleura	UBERON:0000977	98.44	gold quality
visceral pleura	UBERON:0002401	98.42	gold quality
lymph node	UBERON:0000029	98.41	gold quality
tongue squamous epithelium	UBERON:0006919	98.41	gold quality
right adrenal gland cortex	UBERON:0035827	98.39	gold quality
body of pancreas	UBERON:0001150	98.38	gold quality
adrenal gland	UBERON:0002369	98.36	gold quality
left adrenal gland	UBERON:0001234	98.34	gold quality
gluteal muscle	UBERON:0002000	98.33	gold quality
trabecular bone tissue	UBERON:0002483	98.31	gold quality
adrenal cortex	UBERON:0001235	98.30	gold quality
pancreas	UBERON:0001264	98.28	gold quality
saphenous vein	UBERON:0007318	98.27	gold quality
endometrium	UBERON:0001295	98.26	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.25	gold quality
left adrenal gland cortex	UBERON:0035825	98.25	gold quality
vermiform appendix	UBERON:0001154	98.24	gold quality
lower lobe of lung	UBERON:0008949	98.20	gold quality
oral cavity	UBERON:0000167	98.19	gold quality
monocyte	CL:0000576	98.16	gold quality
mononuclear cell	CL:0000842	98.13	gold quality
caecum	UBERON:0001153	98.12	gold quality
bronchial epithelial cell	CL:0002328	98.11	gold quality
leukocyte	CL:0000738	98.10	gold quality
tongue	UBERON:0001723	98.10	gold quality
type B pancreatic cell	CL:0000169	98.08	gold quality
body of tongue	UBERON:0011876	98.08	gold quality
jejunal mucosa	UBERON:0000399	98.06	gold quality
rectum	UBERON:0001052	98.06	gold quality
smooth muscle tissue	UBERON:0001135	98.06	gold quality
hair follicle	UBERON:0002073	98.04	gold quality
pons	UBERON:0000988	98.03	gold quality
epithelium of bronchus	UBERON:0002031	98.02	gold quality
jejunum	UBERON:0002115	98.01	gold quality
skin of hip	UBERON:0001554	98.00	gold quality
gingiva	UBERON:0001828	98.00	gold quality
bronchus	UBERON:0002185	98.00	gold quality
biceps brachii	UBERON:0001507	97.98	gold quality
amniotic fluid	UBERON:0000173	97.95	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.94	gold quality
cervix squamous epithelium	UBERON:0006922	97.93	gold quality
superior surface of tongue	UBERON:0007371	97.91	gold quality
right coronary artery	UBERON:0001625	97.90	gold quality
colonic mucosa	UBERON:0000317	97.89	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	97.89	gold quality
cerebellar vermis	UBERON:0004720	97.89	gold quality
mammalian vulva	UBERON:0000997	97.88	gold quality
pigmented layer of retina	UBERON:0001782	97.88	gold quality
placenta	UBERON:0001987	97.87	gold quality
pericardium	UBERON:0002407	97.87	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.87	gold quality
retina	UBERON:0000966	97.85	gold quality
heart right ventricle	UBERON:0002080	97.85	gold quality
tibia	UBERON:0000979	97.83	gold quality
ovary	UBERON:0000992	97.83	gold quality
bone element	UBERON:0001474	97.83	gold quality
gingival epithelium	UBERON:0001949	97.82	gold quality
middle temporal gyrus	UBERON:0002771	97.82	gold quality
deltoid	UBERON:0001476	97.81	gold quality
popliteal artery	UBERON:0002250	97.81	gold quality
tibial artery	UBERON:0007610	97.81	gold quality
cervix epithelium	UBERON:0004801	97.79	gold quality
pharyngeal mucosa	UBERON:0000355	97.78	gold quality
artery	UBERON:0001637	97.78	gold quality
eye	UBERON:0000970	97.76	gold quality
aorta	UBERON:0000947	97.75	gold quality
palpebral conjunctiva	UBERON:0001812	97.75	gold quality
upper leg skin	UBERON:0004262	97.74	gold quality
zone of skin	UBERON:0000014	97.73	gold quality
skin of abdomen	UBERON:0001416	97.73	gold quality
triceps brachii	UBERON:0001509	97.73	gold quality
uterus	UBERON:0000995	97.71	gold quality
left coronary artery	UBERON:0001626	97.71	gold quality
tonsil	UBERON:0002372	97.71	gold quality
skin of leg	UBERON:0001511	97.70	gold quality
mucosa of urinary bladder	UBERON:0001259	97.69	gold quality
descending thoracic aorta	UBERON:0002345	97.68	gold quality
bone marrow	UBERON:0002371	97.68	gold quality
vastus lateralis	UBERON:0001379	97.67	gold quality
ascending aorta	UBERON:0001496	97.67	gold quality
thoracic aorta	UBERON:0001515	97.67	gold quality
pylorus	UBERON:0001166	97.65	gold quality
quadriceps femoris	UBERON:0001377	97.64	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-10042	yes	14.15
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Tonsil	tissue	144.4	medium
Tongue	tissue	135.6
Thymus	tissue	131.6
Lymph node	tissue	131.5	medium
Adrenal gland	tissue	118.0	high
Frontal cortex	tissue	117.7
Urinary bladder	tissue	114.2	medium
Skeletal muscle	tissue	113.4	medium
Heart muscle	tissue	108.8	low
Caudate putamen	tissue	106.5
Placenta	tissue	100.5	high
Rectum	tissue	96.0	medium
Kidney	tissue	95.8	medium
Parathyroid gland	tissue	94.0	medium
Breast	tissue	93.9	medium
Bone marrow	tissue	93.9	medium
Ovary	tissue	93.8	high
Appendix	tissue	93.6	medium
Pancreas	tissue	89.9	medium
Liver	tissue	86.7	low
Spleen	tissue	83.8	medium
Epididymis	tissue	83.4	medium
Choroid plexus	tissue	83.1
Colon	tissue	82.4	medium
Smooth muscle	tissue	79.9	not detected
Esophagus	tissue	78.7	low
Fallopian tube	tissue	76.2	medium
Small intestine	tissue	74.0	medium
Testis	tissue	73.9	high
Cervix	tissue	73.8	medium
Thyroid gland	tissue	73.5	medium
Duodenum	tissue	73.3	medium
Prostate	tissue	72.4	medium
Pons	tissue	71.9
Skin 1	tissue	70.8	medium
Endometrium 1	tissue	70.0	medium
Seminal vesicle	tissue	68.3	medium
Adipose tissue	tissue	68.2	low
Vagina	tissue	67.8	low
Salivary gland	tissue	66.6	low
Lung	tissue	66.1	medium
Retina	tissue	66.0
Stomach 1	tissue	64.9	high
Locus coeruleus	tissue	64.2
Superior colliculi	tissue	62.8
Pituitary gland	tissue	62.6
Thalamus	tissue	62.5
Hippocampal formation	tissue	60.5
Gallbladder	tissue	60.3	medium
Cerebral cortex	tissue	59.5	medium
Somatosensory cortex	tissue	59.5
Midbrain	tissue	59.4
Septum	tissue	56.3
Occipital cortex	tissue	55.8
Putamen	tissue	55.7
Substantia nigra	tissue	55.5
Hypothalamus	tissue	55.2
Prefrontal cortex	tissue	54.6
Motor cortex	tissue	53.1
Medulla oblongata	tissue	52.6

Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Blood vessel (102.5), Arcuate nucleus (75.6), Lateral hypothalamic area (68.3), Cerebellar cortex (65.3), Ventromedial nucleus (61.8).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ELK1, ELK3, ELK4

miRNA regulators (miRDB)

Targeting CCT8 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

22 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-4645-3P	99.76	69.33	993
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-1283	99.69	72.42	3009
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-802	99.61	67.70	1254
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-618	97.62	67.46	861
HSA-MIR-526B-5P	97.41	67.99	1074
HSA-MIR-125A-3P	97.04	66.92	902

Functional genomics

gnomAD constraint: pLI 1, LOEUF 0.287, missense Z 1.12 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000286788 — one region, missense o/e 0.85. DepMap (CRISPR cell-line fitness): dependent in 98.9% of screened cell lines, common-essential.

Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): SCC-9 (-2.065), EOL-1 (-2.02), U-118 MG (-2.007), HPAF-II (-1.998), HD-MY-Z (-1.965), Daoy (-1.964), LMSU (-1.937), BHT-101 (-1.878), KU812 (-1.865), RERF-LC-AI (-1.865), HCC38 (-1.837), CAL-62 (-1.828), NCI-H2452 (-1.789), Set-2 (-1.774), D283 Med (-1.772).

Literature-anchored findings (GeneRIF, showing 4)

• showed that high CCT8 protein expression might be related to poor outcome of glioma (PMID:26304164)
• data suggest that the GRP94/CCT8/c-Jun/EMT signaling cascade might be a new therapeutic target for HCC (PMID:26718209)
• Ectopic expression of CCT8 also ameliorates the age-associated demise of proteostasis and corrects proteostatic deficiencies in worm models of Huntington’s disease. (PMID:27892468)
• Study demonstrated that CCT8 expression is widely upregulated in esophageal squamous cell carcinoma (ESCC), and enhanced the migration and invasion of ESCC cells, indicating that ectopic CCT8 expression contributes to the highly aggressive nature of ESCC probably by increasing alpha-actin and beta-tubulin expression. (PMID:29620162)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cct8	ENSDARG00000008243
mus_musculus	Cct8	ENSMUSG00000025613
rattus_norvegicus	Cct8	ENSRNOG00000001592
drosophila_melanogaster	CCT8	FBGN0284436
caenorhabditis_elegans		WBGENE00021934

Paralogs (13): PIKFYVE (ENSG00000115020), CCT4 (ENSG00000115484), TCP1 (ENSG00000120438), MKKS (ENSG00000125863), CCT6B (ENSG00000132141), CCT7 (ENSG00000135624), HSPD1 (ENSG00000144381), CCT6A (ENSG00000146731), CCT5 (ENSG00000150753), CCT3 (ENSG00000163468), CCT2 (ENSG00000166226), BBS12 (ENSG00000181004), CCT8L2 (ENSG00000198445)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:107183) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 5 distinct phenotype terms.

Mouse phenotype (MP)	Records
failure of embryo implantation	1
failure of blastocyst to hatch from the zona pellucida	1
preweaning lethality, complete penetrance	1
embryonic lethality prior to organogenesis	1
embryonic lethality prior to organogenesis, complete penetrance	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pongo abelii	Q5RAP1	100.0%	Diamond
Macaca fascicularis	Q4R5J0	99.5%	Diamond
Bos taurus	Q3ZCI9	97.6%	Diamond
Caenorhabditis briggsae	A8X6I9	95.3%	Diamond
Gallus gallus	Q6EE31	93.8%	Diamond
Ambystoma mexicanum	P50157	90.8%	Diamond
Saccharomyces cerevisiae S288C	P47079	55.6%	Diamond
Candida albicans	P47828	55.6%	Diamond
Schizosaccharomyces pombe 972h-	P78921	53.6%	Diamond
Dictyostelium discoideum	Q552J0	53.1%	Diamond
Arabidopsis thaliana	Q94K05	52.7%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
USP16	protein-coding	10600
LINC00189	ncRNA	193629
MAP3K7CL	protein-coding	56911
RWDD2B	protein-coding	10069

Protein

Protein identifiers

T-complex protein 1 subunit theta — P50990 (reviewed: P50990)

Alternative names: CCT-theta, Chaperonin containing T-complex polypeptide 1 subunit 8, Renal carcinoma antigen NY-REN-15

All UniProt accessions (3): P50990, H7C2U0, H7C4C8

UniProt curated annotations — full annotation on UniProt →

Function. Component of the chaperonin-containing T-complex (TRiC), a molecular chaperone complex that assists the folding of actin, tubulin and other proteins upon ATP hydrolysis. The TRiC complex mediates the folding of WRAP53/TCAB1, thereby regulating telomere maintenance. As part of the TRiC complex may play a role in the assembly of BBSome, a complex involved in ciliogenesis regulating transports vesicles to the cilia.

Subunit / interactions. Component of the chaperonin-containing T-complex (TRiC), a hexadecamer composed of two identical back-to-back stacked rings enclosing a protein folding chamber. Each ring is made up of eight different subunits: TCP1/CCT1, CCT2, CCT3, CCT4, CCT5, CCT6A/CCT6, CCT7, CCT8. Interacts with PACRG. Interacts with DNAAF4. Interacts with synaptic plasticity regulator PANTS.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Cilium basal body.

Disease relevance. De novo genetic variants in nearly every subunit of the TRiC complex, including CCT8, have been found in individuals with a broad spectrum of brain malformations, and clinical phenotypes ranging from mild to severe epilepsy, developmental delay, intellectual disability, ataxia, and other features of cerebral malfunction.

Similarity. Belongs to the TCP-1 chaperonin family.

Isoforms (3)

UniProt ID	Names	Canonical?
P50990-1	1	yes
P50990-2	2
P50990-3	3

RefSeq proteins (4): NP_001269836, NP_001269837, NP_001269838, NP_006576* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002194	Chaperonin_TCP-1_CS	Conserved_site
IPR002423	Cpn60/GroEL/TCP-1	Family
IPR012721	Chap_CCT_theta	Family
IPR017998	TCP-1	Family
IPR027409	GroEL-like_apical_dom_sf	Homologous_superfamily
IPR027410	TCP-1-like_intermed_sf	Homologous_superfamily
IPR027413	GROEL-like_equatorial_sf	Homologous_superfamily

Pfam: PF00118

Enzyme classification (BRENDA)

• EC 3.6.4.B10 — (BRENDA: organisms, substrates, inhibitors, Km, kcat entries)

Catalyzed reactions (Rhea)

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (105 total): strand 28, helix 27, binding site 20, modified residue 12, cross-link 6, turn 3, splice variant 2, sequence variant 2, sequence conflict 2, initiator methionine 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

showing 30 of 71 structures by resolution:

PDB	Title	Method	Resolution (Å)
7NVL	Human TRiC complex in closed state with nanobody bound (Consensus Map)	ELECTRON MICROSCOPY	2.5
8SH9	CCT G beta 5 complex best PhLP1 class	ELECTRON MICROSCOPY	2.7
9S72	Human CCT in Closed Conformation	ELECTRON MICROSCOPY	2.71
8SHE	CCT-G beta 5 complex closed state 8	ELECTRON MICROSCOPY	2.8
8SHG	CCT G beta 5 complex closed state 9	ELECTRON MICROSCOPY	2.8
8SHN	CCT-G beta 5 complex closed state 6	ELECTRON MICROSCOPY	2.8
7TTT	The beta-tubulin folding intermediate III	ELECTRON MICROSCOPY	2.9
8SG9	CCT G beta 5 complex closed state 3	ELECTRON MICROSCOPY	2.9
8SGC	CCT G beta 5 complex closed state 2	ELECTRON MICROSCOPY	2.9
8SGL	CCT G beta 5 complex closed state 15	ELECTRON MICROSCOPY	2.9
8SHD	CCT G beta 5 complex closed state 10	ELECTRON MICROSCOPY	2.9
8SHQ	CCT G beta 5 complex closed state 12	ELECTRON MICROSCOPY	2.9
9NOQ	CCT G beta 5 R269E complex state 5	ELECTRON MICROSCOPY	2.9
9NRH	CCT G beta 5 R269E complex state 4	ELECTRON MICROSCOPY	2.9
7NVN	Human TRiC complex in closed state with nanobody and tubulin bound	ELECTRON MICROSCOPY	3
7TRG	The beta-tubulin folding intermediate I	ELECTRON MICROSCOPY	3
8SG8	CCT G beta 5 complex closed state 1	ELECTRON MICROSCOPY	3
8SHA	CCT-G beta 5 complex closed state 4	ELECTRON MICROSCOPY	3
8SHF	CCT-G beta 5 complex closed state 7	ELECTRON MICROSCOPY	3
8SHL	CCT G beta 5 complex closed state 5	ELECTRON MICROSCOPY	3
8SHO	CCT G beta 5 complex close state 11	ELECTRON MICROSCOPY	3
8SHP	CCT G beta 5 complex closed state 13	ELECTRON MICROSCOPY	3
8SHT	CCT G beta 5 complex closed state 14	ELECTRON MICROSCOPY	3
9NPW	CCT G beta 5 R269E complex state 2	ELECTRON MICROSCOPY	3
9NQ1	CCT G beta 5 R269E complex state 1	ELECTRON MICROSCOPY	3
9NRG	CCT G beta 5 R269E complex state 3	ELECTRON MICROSCOPY	3
7NVM	Human TRiC complex in closed state with nanobody Nb18, actin and PhLP2A bound	ELECTRON MICROSCOPY	3.1
7X0A	Cryo-EM structure of human TRiC-NPP state	ELECTRON MICROSCOPY	3.1
7X0S	Human TRiC-tubulin-S3	ELECTRON MICROSCOPY	3.1
8HKI	Human TRiC open state	ELECTRON MICROSCOPY	3.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P50990-F1	87.85	0.58

Antibody-complex structures (SAbDab)

4 antibodies co-crystallized with this protein: 7NVL, 7NVM, 7NVN, 7NVO

Human Protein Atlas

Protein class: Predicted intracellular proteins, Plasma proteins, Essential proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): connecting piece; end piece; nucleoplasm; cytosol; mid piece; principal piece

Antibody reliability (HPA): IH enhanced · IF uncertain

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (20)

Position	Role
102	ADP
102	ATP
103	ADP
169	ADP
170	ADP
170	ATP
171	ADP
171	ATP
412	ADP
412	ATP
499	ADP
499	ATP
504	ATP
47	ADP
48	ADP
99	Mg(2+)
100	ADP
100	ATP
101	ADP
101	ATP

Post-translational modifications (18)

Type	Positions
N-acetylalanine	2
Phosphoserine	23, 162, 213, 269, 317, 537
Phosphotyrosine	30, 505
N6-acetyllysine	318, 400, 466
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo2)	224, 254, 260, 534, 539
Glycyl lysine isopeptide (lys-gly) (interchain with g-cter in sumo1)	459

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 16; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

16 pathways:

ID	Pathway	Evidence
R-HSA-5620922	BBSome-mediated cargo-targeting to cilium	curated
R-HSA-6814122	Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding	curated
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-390471	Association of TriC/CCT with target proteins during biosynthesis	electronic
R-HSA-5620920	Cargo trafficking to the periciliary membrane	—
R-HSA-390466	Chaperonin-mediated protein folding	—
R-HSA-5617833	Cilium Assembly	—
R-HSA-389958	Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	—
R-HSA-390450	Folding of actin by CCT/TriC	electronic
R-HSA-389960	Formation of tubulin folding intermediates by CCT/TriC	electronic
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—
R-HSA-392499	Metabolism of proteins	—
R-HSA-1852241	Organelle biogenesis and maintenance	—
R-HSA-389957	Prefoldin mediated transfer of substrate to CCT/TriC	electronic
R-HSA-391251	Protein folding	—

MSigDB gene sets: 250 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GOBP_RNA_TEMPLATED_DNA_BIOSYNTHETIC_PROCESS, GOBP_SINGLE_FERTILIZATION, GOBP_CHROMOSOME_ORGANIZATION, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_POSITIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOCC_SECRETORY_GRANULE, MODULE_151, TTTGTAG_MIR520D, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_TELOMERE_MAINTENANCE_VIA_TELOMERE_LENGTHENING, GOBP_TELOMERE_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOCC_MICROTUBULE_ORGANIZING_CENTER

GO Biological Process (5): protein folding (GO:0006457), positive regulation of telomere maintenance via telomerase (GO:0032212), protein stabilization (GO:0050821), positive regulation of protein localization to Cajal body (GO:1904871), positive regulation of telomerase RNA localization to Cajal body (GO:1904874)

GO Molecular Function (8): ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), protein folding chaperone (GO:0044183), cadherin binding (GO:0045296), ATP-dependent protein folding chaperone (GO:0140662), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (12): zona pellucida receptor complex (GO:0002199), extracellular region (GO:0005576), cytoplasm (GO:0005737), centrosome (GO:0005813), cytosol (GO:0005829), chaperonin-containing T-complex (GO:0005832), microtubule (GO:0005874), secretory granule lumen (GO:0034774), azurophil granule lumen (GO:0035578), cell body (GO:0044297), extracellular exosome (GO:0070062), ficolin-1-rich granule lumen (GO:1904813)

Reactome top-level categories

9 top-level categories:

Category	Pathways
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	3
Chaperonin-mediated protein folding	3
Cargo trafficking to the periciliary membrane	1
Innate Immune System	1
Immune System	1
Protein folding	1
Metabolism of proteins	1
Organelle biogenesis and maintenance	1
Assembly of the 9+0 primary cilium	1

GO top-level categories

45 GO namespaces:

Category	Terms
cellular anatomical structure	4
ATP-dependent activity	2
cellular process	1
protein maturation	1
telomere maintenance via telomerase	1
regulation of telomere maintenance via telomerase	1
positive regulation of telomere maintenance via telomere lengthening	1
positive regulation of DNA biosynthetic process	1
regulation of protein stability	1
positive regulation of protein localization to nucleus	1
protein localization to Cajal body	1
regulation of protein localization to Cajal body	1
positive regulation of biological process	1
telomerase RNA localization to Cajal body	1
regulation of telomerase RNA localization to Cajal body	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
ribonucleoside triphosphate phosphatase activity	1
molecular_function	1
protein folding	1
cell adhesion molecule binding	1
protein folding chaperone	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
chaperonin-containing T-complex	1
protein-containing complex	1
intracellular anatomical structure	1
centriole	1
microtubule organizing center	1
cytoplasm	1
cytosol	1
protein folding chaperone complex	1
microtubule cytoskeleton	1
polymeric cytoskeletal fiber	1
secretory granule	1
cytoplasmic vesicle lumen	1
vacuolar lumen	1
secretory granule lumen	1
azurophil granule	1
extracellular vesicle	1
intracellular organelle lumen	1
ficolin-1-rich granule	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 11 of 26 annotations. The rest are phylogenetic / computational / electronic (IEA).

11 experimentally-supported GO terms:

GO term	NS	Evidence
positive regulation of telomere maintenance via telomerase	BP	mutant phenotype
protein folding	BP	direct assay
protein stabilization	BP	mutant phenotype
centrosome	CC	direct assay
chaperonin-containing T-complex	CC	direct assay
cytoplasm	CC	direct assay
cytosol	CC	direct assay
extracellular exosome	CC	high-throughput assay
microtubule	CC	direct assay
cadherin binding	MF	high-throughput assay
protein folding chaperone	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 3,396 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCT8	CCT2	P78371	703
CCT8	TCP1	P17987	700
CCT8	CCT3	P49368	694
CCT8	CCT5	P48643	680
CCT8	CCT4	P50991	661
CCT8	CCT7	Q99832	656
CCT8	CCT6A	P40227	587
CCT8	TSR1	Q2NL82	576
CCT8	HSPD1	P10809	482
CCT8	CCT6B	Q92526	478
CCT8	POLR2B	P30876	466
CCT8	HSPA4	P34932	435
CCT8	HSPA8	P11142	433
CCT8	HSP90AA1	P07900	432
CCT8	HSP90AB1	P08238	431

IntAct

Human interaction partners of CCT8 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

17 partners by confidence:

Partner	Interaction type	MIscore	Records
CCT6A	physical association	0.750	4
HTT	physical association	0.670	3
TCP1	physical association	0.670	1
BAG6	physical association	0.560	3
BRME1	physical association	0.560	3
CDHR3	physical association	0.560	3
MAGEB6	physical association	0.560	3
SNX12	physical association	0.560	3
TUBA1B	physical association	0.560	3
SCEL	physical association	0.400	1
YWHAZ	physical association	0.400	1
PADI4	association	0.350	1
PDCD5	association	0.350	1
MAP3K1	physical association	0.000	1
MAP3K3	physical association	0.000	1
RELA	physical association	0.000	1
TBK1	physical association	0.000	1

BioGRID (851 interactions; top human partners by supporting records in a sample of 600 records): CCT3 (Co-fractionation; 7 records), CCT2 (Co-fractionation; 6 records), CCT7 (Co-fractionation; 6 records), CCT4 (Co-fractionation; 5 records), CCT5 (Co-fractionation; 5 records), CCT6A (Co-fractionation; 5 records), HDAC1 (Affinity Capture-MS; 4 records), PDCL3 (Co-fractionation; 4 records), TCP1 (Co-fractionation; 4 records), DCAF7 (Affinity Capture-MS; 3 records), FBXW4 (Affinity Capture-MS; 3 records), ILK (Affinity Capture-MS; 3 records), PARK2 (Affinity Capture-MS; 3 records), POC1A (Affinity Capture-MS; 3 records), PPP2CA (Affinity Capture-MS; 3 records)

SIGNOR signaling

1 signaling interactions:

A	Effect	B	Mechanism
CCT8	“form complex”	TRiC	binding

Protein complexes (CORUM) (2)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

2 complexes by size:

Complex	Subunits	Members
BBS-chaperonin complex	10	BBS7, CCT2, CCT3, CCT5, CCT8, MKKS, CCT4, TCP1, BBS10, BBS12
CCT complex (chaperonin containing TCP1 complex)	8	CCT3, CCT4, CCT5, CCT6A, CCT7, CCT8, TCP1, CCT2

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 17 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by Interleukins	5	29.2×	4e-05
Cytokine Signaling in Immune system	6	22.2×	2e-05

Disease & clinical

Genetic variants

Variant evidence for CCT8: 93 ClinVar records (0 pathogenic / likely pathogenic); 3 GWAS associations.

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	3
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 25 predictions of 1,206):

Position(s)	Effect	Δscore	Sites
21:29060539–29060540	donor_loss	1.0000	5
21:29061251–29061252	donor_loss	1.0000	4
21:29061280	donor_gain	1.0000
21:29061329	donor_gain	1.0000
21:29061494–29061495	donor_loss	1.0000	5
21:29061584	acceptor_gain	1.0000
21:29061588	acceptor_gain	1.0000
21:29062126–29062127	donor_loss	1.0000	5
21:29062169	donor_gain	1.0000
21:29062249	acceptor_gain	1.0000

AlphaMissense

1,780 missense substitutions predicted likely pathogenic (of 3,598 scored), across 436 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D68	8	0.995	0.999
H80	8	0.991	0.999
D99	8	0.987	0.996
D522	8	0.986	0.998
D394	8	0.976	0.995
D387	8	0.968	0.994
N32	8	0.948	0.999
D200	8	0.940	0.991
D499	8	0.937	0.990
F363	8	0.917	0.997
D320	8	0.915	0.989
D393	8	0.911	0.968
D386	8	0.907	0.989
M526	8	0.902	0.990
F64	8	0.894	0.987
H471	8	0.893	0.988
F223	8	0.882	0.985
N455	8	0.877	0.992
F197	8	0.876	0.988
D405	8	0.868	0.964

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

6 prognostic cancer types:

Cancer	Prognostic	p-value
Liver Hepatocellular Carcinoma (TCGA)	unfavorable	3.02e-07
Liver Hepatocellular Carcinoma (validation)	unfavorable	5.27e-05
Lung Adenocarcinoma (TCGA)	unfavorable	0.0001
Head and Neck Squamous Cell Carcinoma (TCGA)	unfavorable	0.000133
Lung Adenocarcinoma (validation)	unfavorable	0.000279
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	0.000308

Disease associations

OMIM: gene MIM:617786 | disease phenotypes:

GenCC curated gene-disease

2 curated gene-disease records:

Disease	Classification	Inheritance	Records
neurodevelopmental disorder	Limited	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal dominant

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (9 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

9 panels:

Panel	Rating
Cerebral malformation	amber
Early onset or syndromic epilepsy	amber
Fetal anomalies	amber
Hypotonic infant	amber
Intellectual disability	amber
Leukodystrophy, childhood onset	amber
Malformations of cortical development	amber
Paediatric disorders	amber
Unexplained death in infancy and sudden unexplained death in childhood	amber

Mondo (2): neurodevelopmental disorder (MONDO:0700092), complex neurodevelopmental disorder (MONDO:0100038)

GWAS associations

3 associations:

Study	Trait	p-value
GCST010796_581	Electrocardiogram morphology (amplitude at temporal datapoints)	7e-9
GCST010796_582	Electrocardiogram morphology (amplitude at temporal datapoints)	1e-8
GCST010796_583	Electrocardiogram morphology (amplitude at temporal datapoints)	2e-8

EFO canonical traits (from GWAS)

1 canonical traits:

EFO ID	Trait name
EFO:0004327	electrocardiography

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295775 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 1 human assays (2 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5653589	KD	1440 nM

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.73	Kd	18.64	nM	CHEMBL3752910
7.73	ED50	18.64	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148026: Binding affinity to human CCT8 incubated for 45 mins by Kinobead based pull down assay	kd	0.0186	uM

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression	3
Arsenic Trioxide	affects binding, decreases reaction, increases expression	2
Smoke	decreases expression	2
Tetrachlorodibenzodioxin	decreases expression, affects expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
FR900359	increases phosphorylation	1
bisphenol F	increases expression	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
bisphenol A	decreases expression	1
sodium arsenate	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression	1
arsenite	affects binding, increases reaction	1
ochratoxin A	affects expression	1
cupric oxide	increases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
epigallocatechin gallate	decreases expression	1
microcystin RR	increases expression	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	affects expression	1
tanespimycin	affects cotreatment, decreases expression	1
bisphenol B	increases expression	1
bromovanin	increases expression	1
bisphenol S	increases expression	1
jinfukang	decreases expression	1
VER 155008	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Air Pollutants	increases abundance, affects expression	1
Arbutin	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118778	Binding	Binding affinity to CCT8 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — *Bioorg Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 212 trials:

NCT	Phase	Status	Title
NCT04586348	Phase 4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	Phase 4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	Phase 3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	Phase 3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	Phase 3	RECRUITING	Reducing Missed Appointments
NCT07377032	Phase 3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	Phase 2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	Phase 2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	Phase 2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	Phase 1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	Phase 1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	Phase 2/3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	Phase 2/3	COMPLETED	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	Early Phase 1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	COMPLETED	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice
NCT03381027	Not specified	COMPLETED	BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)
NCT03388294	Not specified	COMPLETED	Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders
NCT03410810	Not specified	UNKNOWN	Childhood Outcomes of Preterm Brain Abnormalities
NCT03492060	Not specified	RECRUITING	Longitudinal Study of Neurogenetic Disorders
NCT03577756	Not specified	COMPLETED	Neurodevelopmental Assessment of Infants With Cystic Fibrosis
NCT03654248	Not specified	COMPLETED	Let’s Get Organized in Adult Psychiatric/habilitation Care
NCT03659279	Not specified	COMPLETED	Let’s Get Organized Feasibility Study
NCT03722615	Not specified	COMPLETED	Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
NCT03770832	Not specified	ACTIVE_NOT_RECRUITING	Wearable Sensors and Video Recordings to Monitor Motor Development
NCT03830879	Not specified	RECRUITING	Shenzhen Birth Cohort Study
NCT03835689	Not specified	COMPLETED	Strongest FamiliesTM Neurodevelopmental
NCT03882788	Not specified	COMPLETED	The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
NCT03922087	Not specified	COMPLETED	No-worry Baby Project
NCT03977259	Not specified	ACTIVE_NOT_RECRUITING	Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development
NCT04043572	Not specified	UNKNOWN	The Biomarkers of Neurological Disease in Utero Study
NCT04096430	Not specified	RECRUITING	Evaluation of Effectiveness of Child-oriented Goal-setting in Paediatric Rehabilitation (the ENGAGE Approach)
NCT04108273	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children
NCT04201509	Not specified	COMPLETED	Validity of Neurocognitive Assessment Methods in Childhood ADHD
NCT04233775	Not specified	UNKNOWN	Altered Cerebral Growth and Development in Infants With Congenital Heart Disease
NCT04313283	Not specified	COMPLETED	Translating Peer-to-Peer Support Into a Clinical Setting

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for CCT8 across ~30M SureChEMBL compounds — explore on Sugi Predict.